The Suppression of Ovarian Function Trial (SOFT) randomly assigned premenopausal women with hormone receptor-positive breast cancer to 5 years of adjuvant tamoxifen, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. After 8 years, SOFT reported a significant reduction in recurrence and improved overall survival for those who had received tamoxifen plus OFS, compared with those who had received tamoxifen alone. After 12 years, disease-free survival remained significantly improved for those who had received tamoxifen plus OFS, compared with those receiving tamoxifen alone. A list of publications from this trial can be seen here.
An excellent overview, written in 2022, of the role of ovarian suppression in managing hormone-sensitive breast cancer in premenopausal women can be read here.
|Connolly 2022 Ovarian suppression.pdf||100.77 KB|